This study represents paclitaxel-containing lipidbased solid lipid nanoparticles (SLNs) with polyethylene glycol (PEG)-modified surfaces and tumor-targeting ligand. The prepared paclitaxelcontaining tumor-targeting SLNs had a monodispersed size distribution with a neutralized surface charge. Paclitaxel loaded efficiently into these SLNs. In pre-clinical human cancer xenograft mouse model studies, these SLNs had superior anti-tumor activity to in-class nano-particular therapeutics in clinical use, and yielded long-term complete responses.
INTRODUCTION
Many nanoparticle-based approaches to cancer therapy have failed, due to their inherent toxicity, limited efficacy and stability. 1, 2 To resolve these engineering hurdles is an important step towards the successful development of novel nano-therapeutics.
In this study, we developed anti-cancer therapeutic lipid nanoparticles, which mimic LDL (low-density lipoprotein). This therapeutic nanoparticle contained water-insoluble anti-cancer drug, paclitaxel, in the core and have tumortargeting ligand, cetuximab, covalently conjugated on the polyethylene glycol (PEG)-modified surface. Not only did we describe the engineering aspects of manufacturing these novel nanoparticles in detail, but we also validated their in vivo functionality through a well-controlled pre-clinical animal model studies with other clinically-approved in-class nanoparticles.
EXPERIMENTAL METHODS
Paclitaxel-containing SLNs (tSLNs) for therapeutics were manufactured using a modified solvent-emulsification method. 3 Targeting moiety (cetuximab) was conjugated to the tSLNs using the hetero-bifunctional cross-linking agent, NHS-PEGmaleimide. Briefly, NHS-PEG-maleimide (2.7 mg) and NHS-PEG-methoxy (6.3 mg) were dissolved in deionized water at a concentration of 1 mg/ml and added to 1 ml of tSLN solution (5 mg/ml) with vigorous rotation for 12 hours at 4 ºC to covalently link between NHS groups on the PEG derivatives and primary amine groups on the tSLN surface. Thiolated cetuximab pretreated with Traut's reagent, 2-iminothiolane, was then conjugated to the PEGylated tSLNs (PtSLNs). Thiolated cetuximab (1.1 mg) was incubated with 1 ml of PtSLN (5 mg/ml) at 4 ºC overnight. Thioether bond formation between the PtSLNs and thiolated cetuximab yielded cetuximab-conjugated PtSLNs (cetuxi-PtSLNs). Prepared SLN formulations were observed by AFM (XE-100, Park system, Korea) and Zetasizer nanoseries nano-ZS (Malvern Instruments LTD., Malvern, UK).
We also studied the anti-tumor efficacy of cetuxi-PtSLNs in comparison with the conventionally used taxane-delivering formulations, Taxol ® and Genexol ® -PM. Female SPF BALB/C-nu mice bearing lung cancer cell lines, H1975 cells in the right flank and H1650 cells in the left flank, were randomly divided into three groups (n=6 mice/group) and cetuxi-PtSLNs at their effective tolerable dose, eTD (22 mg paclitaxel/kg) and Taxol were administered intravenously once a week for 3 weeks. Tumor size was monitored with calipers once a week for 11 weeks and tumor volume was calculated.
RESULTS AND DISCUSSION
The prepared cetuxi-PtSLNs ( Figure 1 ) had a mono-dispersed size distribution (160.4 ± 0.9 nm) and neutralized surface charge value of -1.3 ± 1.0 mV (Figure 2 ). 
-test).
Paclitaxel loaded efficiently into these SLNs (11 ± 0.8% w/w) as shown in table 1. The total paclitaxel loading amount in water (550 ± 40 μg/ml) at 5.0 mg/ml of SLN formulations was significantly higher than the solubility of paclitaxel in water (<1 μg/ml), suggesting that the improved solubilization of paclitaxel was mediated primarily by molecular dissolution in the hydrophobic core of the SLNs. Table 1 . The efficiency of paclitaxel encapsulation into the cetuxi-PtSLNs (determined by HPLC)
In pre-clinical human cancer xenograft mouse model studies, the targeted-PtSLNs exhibited superior anti-tumor activity to in-class nanoparticular therapeutics in clinical use, and yielded long-term complete responses (Figure 3) . 
CONCLUSION
Because of their excellent nano-scale reservoir structures for efficient encapsulation of therapeutic, high tumor targeting ability, and bio-safety, tumortargeting SLN formulations can potentially be used as delivery vehicles for water-insoluble anti-cancer drugs, facilitating effective cancer therapy while reducing non-specific side effects.
